Form 4: Galectin Therapeutics Director Acquires Shares and Options in Lieu of Cash Compensation

Richard E. Uihlein, a director at Galectin Therapeutics, acquired 32,520 shares and 60,000 stock options as part of his compensation.

Summary

• Richard E. Uihlein, a director of Galectin Therapeutics, has acquired 32,520 shares of common stock at a price of $1.23 per share.
• These shares were issued in lieu of a $40,000 cash retainer and meeting fees for 2024.
• The shares vest at a rate of 25% at the end of each calendar quarter in 2024.
• Uihlein also acquired 60,000 stock options with an exercise price of $1.23 per share.
• These options vest 100% on December 31, 2025, and expire on January 23, 2035.
• Uihlein also indirectly owns 27,710 shares through the Ed Uihlein Family Foundation, where he is president and director.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns interests. There are no indications of any negative issues.

Positives

• The acquisition of shares and options aligns the director's interests with those of the shareholders.
• The vesting schedule of the shares and options encourages long-term commitment from the director.

Industry Context

This is a standard practice for compensating board members and aligning their interests with the company's performance. It is common for companies to use equity-based compensation to attract and retain directors.

Comparison to Industry Standards

• Equity-based compensation is a common practice for directors in the biotechnology industry.
• The vesting schedule of the shares and options is typical for director compensation packages.
• The use of stock options with a 10-year term is also a standard practice.

Stakeholder Impact

• The transaction has a positive impact on shareholders as it aligns the director's interests with the company's performance.
• The vesting schedule of the shares and options encourages long-term commitment from the director.

Key Dates

Keywords

Galectin Therapeutics, Richard E. Uihlein, stock options, share acquisition, director compensation, insider trading, equity incentive plan